Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622869 | 0.89 | L3MBTL1 (0.56) | LMNAL3MBTL1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL26697138 | 0.84 | NPC1 (0.48) | RAB9ALMNAL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL10517984 | 0.81 | ALDH1A1 (0.51) | RAB9ALMNAL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4172605 | 0.80 | L3MBTL1 (0.70) | RAB9ALMNAL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4237309 | 0.80 | L3MBTL1 (0.56) | RAB9ALMNAL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL6830332 | 0.80 | L3MBTL1 (0.49) | RAB9ACXCL8L3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL1703904 | 0.79 | RAB9A (0.72) | RAB9ALMNANPC1SMN1; SMN2MAPT | |
| SCHEMBL31111478 | 0.79 | RAB9A (0.72) | RAB9ALMNANPC1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL11164652 | 0.79 | L3MBTL1 (0.68) | RAB9ALMNAL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL27547012 | 0.79 | L3MBTL1 (0.68) | RAB9ALMNAL3MBTL1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | RAB9A 1778/4885LMNA 3515/4885CXCL8 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.